Cost increases initially spurred by supply chain disruptions by COVID-19 pandemic have been noted by businesses across consumer product industries since soon after novel coronavirus spread accelerated in early 2020.  More recently, OTC drug, nutritional supplement and personal care product providers began noting inflation’s influence on costs.

Commissioner nominee strikes an optimistic note as former FDA heads raise concerns about the decrease in agency credibility during the pandemic.

Deal Snapshot: At a same-day conference, Amgen’s CEO outlined the importance of AI/ML to the company’s drug development strategy, as numerous large biopharma companies have recently made similar deals.

Plus deals involving GC Cell/Rivaara Immune, Sperogenix/Santhera, EOFlow/Zihipp, Grand/ITM, Tasly/Sutro, LegoChem/Iksuda, Nuance/Aerogen, Frontier/AffiRiS and Piramal/Yapan.